Conclusion: The overall anti-HCV prevalence was higher in males and among those aged 30–59 years. The anti-HCV positivity rate has been declining since the launch of the HCV elimination program in April 2015. Although significant progress has been made, a substantial proportion of infected people need to be identified, confirmed, and linked to care. SAT274 Evaluation of hepatitis B virus (HBV) epidemiology, vaccine impact and treatment eligibility: a census-based community serological survey in Blantyre, Malawi Alexander Stockdale 1,2 , James Meiring 2,3 , Isaac T. Shawa 2,4 , Deus Thindwa 5 , Niza Silungwe 2 , Maurice Mbewe 2 , Collins Mitambo 6 , Rabson Kachala 6 , Benno Kreuels 7 , Pratiksha Patel 2 , Priyanka Patel 2 , Stephen Gordon 2,8 , Anna Maria Geretti 1 , Melita Gordon 1,2 . 1 University of Liverpool, Institute of Infection and Global Health, Liverpool, United Kingdom; 2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; 3 University of Oxford, Oxford Vaccine Group, Department of Paediatrics, Oxford, United Kingdom; 4 College of Medicine, Faculty of Biomedical Science and Health Professions, Blantyre, Malawi; 5 London School of Hygiene & Tropical Medicine, Department of Infectious Disease Epidemiology, London, United Kingdom; 6 Ministry of Health Malawi, Lilongwe, Malawi; 7 Bernhard Nocht Institute for Tropical Medicine, Department of Tropical Medicine, Hamburg, Germany; 8 Liverpool School of Tropical Medicine, Liverpool, United Kingdom Email: a.stockdale@liverpool.ac.uk Background and Aims: Hepatitis B is the leading cause of cirrhosis and hepatocellular carcinoma in sub-Saharan Africa. To achieve WHO targets of reducing mortality by 65% by 2030, antiviral treatment programmes are needed. Epidemiological data are required to inform an effective public health response and anticipate treatment needs. Method: Infant HBV vaccination began in Malawi in 2002. We conducted a census and serological survey in Blantyre in 2016–18. We selected individuals from the census for serosurvey participation by probability sampling. We estimated HBV prevalence using post- stratification proportional fitting to census age-sex distribution. HBsAg-positive participants were evaluated for treatment eligibility. We estimated vaccine impact by comparing HBsAg prevalence of individuals born 5 years before and after vaccine implementation. Figure: HBsAg prevalence among serosurvey participants stratified by age and sex and vaccine coverage. Results: Of 97,386 censused individuals, 6,073 were sampled in the serosurvey and tested for HBsAg. HBV prevalence was 5.1% (95% CI 4.3–6.1) among adults and 0.3% (0.1–0.6) among children born after vaccine introduction. Three-dose vaccination coverage was 97.4% (1141/1172) in children ≤10 years. Vaccine impact was 95.8% (70.3– 99.4). Treatment eligibility was assessed in 94/150 HBsAg positive adults, among whom 24 (26%) were HIV positive and 16/24 (67%) were receiving tenofovir-containing antiretroviral therapy. Among 69 HIV negative individuals, 2%, 6% and 9% were eligible for treatment by WHO, EASL and AASLD criteria respectively. Projected to the national population, 25586 (95% CI 7172–65519) people will require HBV treatment by EASL criteria. Conclusion: In an urban township in Malawi, HBV prevalence was 5.1% among unvaccinated adults and infant HBV vaccination was associated with a vaccine impact of 96%. Among HBsAg-positive adults, one quarter were HIV-positive and 3–9% of HIV-negative adults required antiviral therapy. SAT275 HCV in addiction care: different epidemiology, excellent treatment results Ana Arencibia Almeida 1 , Andrea Afonso Díaz 2 , Silvia Acosta-López 1 , Luz Goretti Santiago Gutierrez 3 , Pilar Díaz Ruiz 4 , Magdalena Lara 5 , Antonio González Rodríguez 1 , Javier García Solo de Zaldívar 1 , Francisco Andrés Pérez Hernández 1 , Angel David Febles Gonzalez 1 . 1 Hospital Nuestra Señora de La Candelaria, Gastroenterology & Hepatology, Santa Cruz de Tenerife, Spain; 2 Hospital Nuestra Señora de La Candelaria, Internal Medicine; 3 San Miguel Adicction Care Unit, Santa Cruz de Tenerife; 4 Hospital Nuestra Señora de La Candelaria, Pharmacy Department, Santa Cruz de Tenerife, Spain; 5 Hospital Nuestra Señora de La Candelaria, Department of Microbiology, Santa Cruz de Tenerife Email: a.arencibiaa@yahoo.es Background and Aims: Patients treated in addiction care units (ACU) have a higher prevalence of hepatitis C virus (HCV). There is not much evidence about its access to treatment and its results. Our aim is: 1) To determine the epidemiological characteristics and results of treat- ment in the registered population in ACU treatedwith direct-acting antivirals (DAA). 2) Compare with a general cohort treated in the same period of time. Method: 1) Inclusion criteria: population with positive RNA-HCV test treated with DAA. 2) 2 groups were analyzed: HCV population registered in ACU and/or Penitentiary Center (HACU) and general population (GP). 3) Variables: age, sex, viral genotype, fibrosis stage, response to treatment (SVR12). Using the statistical package SPSS version 25. Continuous variables as means ± SD, discrete as frequen- cies (%). Correlation between qualitative variables using Pearson’s Chi square (significant p < 0.05). Results: HACU (n = 198 patients) and GP (n = 948 patients). Mean age (interval) years: HACU 46 (24–63) and GP 53 (18–56). Men (%): HACU 92%, GP 61%. Genotypes (1a/1b/2/3/4)%: HACU (42.3/9.5/0/29.6/8.46) vs. GP (30.2/38.7/2.11/18.5/9.07). 16 patients (8 from each group) were not genotyped. Fibrosis stage was determined by hepatic elastography and cirrhosis was defined by obvious clinical and/or image data. The distribution by stages (F0-1/F2/F3/F4)% was: HACU (31.2/20.6/18/29.6) vs. GP (27.3/22.7/16/32.5). Fibrosis stage was not established in 1 patient of the HACU group and 14 of the GP. We found no significant differences when comparing sex and genotype, age and fibrosis stage, genotype and fibrosis stage within the patients of the HACU group. When comparing HACU against GP significant differences were observed by genotype (p: 0.001) observing a higher prevalence of genotype 3 in HACU. However, no significant differences were observed by fibrosis stage (p: 0.55). We have the result of treatment in 189 patients of the HACU group (4 patients lost were recovered and sustained virological response -SVR12- was confirmed and 2 who abandoned therapyare currently in re-treatment). The SVR12 for ITT was 91.4% in HACU vs. 95.2% in GP; in the PPanalysis SVR 12 was 100% in HACU vs. 99.5% in GP. POSTER PRESENTATIONS S790 Journal of Hepatology 2020 vol. 73 | S653–S915